Bruce Jacobs's most recent trade in Kymera Therapeutics Inc was a trade of 61,378 Common Stock done at an average price of $5.3 . Disclosure was reported to the exchange on June 30, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.33 per share. | 30 Jun 2026 | 61,378 | 321,992 | - | 5.3 | 327,145 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2026 | 61,378 | 0 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 114.77 per share. | 30 Jun 2026 | 51,375 | 262,207 | - | 114.8 | 5,896,288 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 115.82 per share. | 30 Jun 2026 | 7,971 | 254,236 | - | 115.8 | 923,178 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 116.99 per share. | 30 Jun 2026 | 6,153 | 248,083 | - | 117.0 | 719,862 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 114.19 per share. | 30 Jun 2026 | 4,110 | 313,582 | - | 114.2 | 469,311 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 117.70 per share. | 30 Jun 2026 | 3,200 | 244,883 | - | 117.7 | 376,649 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 111.57 per share. | 30 Jun 2026 | 1,700 | 318,792 | - | 111.6 | 189,664 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 110.54 per share. | 30 Jun 2026 | 1,500 | 320,492 | - | 110.5 | 165,810 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 112.79 per share. | 30 Jun 2026 | 1,100 | 317,692 | - | 112.8 | 124,067 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 02 Jun 2026 | 12,653 | 260,241 | - | 2.1 | 26,318 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2026 | 12,653 | 0 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 15,000 | 12,653 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 18 May 2026 | 15,000 | 247,588 | - | 2.1 | 31,200 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 35,300 | 35,300 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 17,650 | 245,059 | - | 0 | Common Stock | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 89.66 per share. | 02 Mar 2026 | 4,113 | 237,483 | - | 89.7 | 368,761 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 85.04 per share. | 02 Mar 2026 | 2,519 | 234,472 | - | 85.0 | 214,207 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 87.75 per share. | 02 Mar 2026 | 2,039 | 243,020 | - | 87.8 | 178,924 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 85.78 per share. | 02 Mar 2026 | 1,437 | 233,035 | - | 85.8 | 123,267 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 88.50 per share. | 02 Mar 2026 | 1,424 | 241,596 | - | 88.5 | 126,025 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 84.00 per share. | 02 Mar 2026 | 492 | 236,991 | - | 84.0 | 41,326 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 86.62 per share. | 02 Mar 2026 | 447 | 232,588 | - | 86.6 | 38,721 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 17 Sep 2025 | 79,220 | 227,409 | - | 50.0 | 3,961,380 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 17 Sep 2025 | 79,220 | 306,629 | - | 2.1 | 164,778 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2025 | 42,246 | 27,653 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2025 | 36,974 | 0 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 25,000 | 69,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 31 Mar 2025 | 25,000 | 226,886 | - | 2.1 | 52,000 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 30,000 | 208,921 | - | 0 | Common Stock | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.33 per share. | 03 Mar 2025 | 5,754 | 203,167 | - | 30.3 | 174,502 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.00 per share. | 03 Mar 2025 | 1,281 | 201,886 | - | 31.0 | 39,717 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 10 Jan 2025 | 10,000 | 178,921 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jan 2025 | 10,000 | 94,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 27 Jun 2024 | 25,000 | 168,554 | - | 2.1 | 52,000 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2024 | 25,000 | 104,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 187,500 | 187,500 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 31,250 | 146,285 | - | 0 | Common Stock | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 41.41 per share. | 01 Mar 2024 | 2,378 | 143,907 | - | 41.4 | 98,481 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 42.39 per share. | 01 Mar 2024 | 1,301 | 142,606 | - | 42.4 | 55,153 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 43.25 per share. | 01 Mar 2024 | 255 | 142,351 | - | 43.3 | 11,030 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 02 Jun 2023 | 10,000 | 115,035 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2023 | 10,000 | 129,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 142,500 | 142,500 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 23,750 | 105,938 | - | 0 | Common Stock | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.88 per share. | 01 Mar 2023 | 1,056 | 104,882 | - | 30.9 | 32,607 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.40 per share. | 01 Mar 2023 | 314 | 104,568 | - | 31.4 | 9,859 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 21 Oct 2022 | 10,000 | 81,279 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2022 | 10,000 | 139,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 17 Oct 2022 | 10,000 | 71,279 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2022 | 10,000 | 149,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 20,000 | 159,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 03 May 2022 | 20,000 | 60,814 | - | 2.1 | 41,600 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 13,300 | 40,814 | - | 0 | Common Stock | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 14 Jan 2022 | 10,000 | 27,514 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 10,000 | 179,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 12 Jan 2022 | 15,000 | 32,514 | - | 2.1 | 31,200 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2022 | 15,000 | 36,974 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 52.13 per share. | 12 Jan 2022 | 7,151 | 18,936 | - | 52.1 | 372,788 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 51.21 per share. | 12 Jan 2022 | 6,427 | 26,087 | - | 51.2 | 329,149 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 53.27 per share. | 12 Jan 2022 | 1,422 | 17,514 | - | 53.3 | 75,747 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2021 | 10,000 | 199,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 23 Nov 2021 | 10,000 | 17,256 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2021 | 10,000 | 209,899 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 03 Sep 2021 | 10,000 | 17,256 | - | 2.1 | 20,800 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 60.05 per share. | 03 Sep 2021 | 8,500 | 8,756 | - | 60.1 | 510,436 | Common Stock |
| Kymera Therapeutics Inc | Bruce Jacobs | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 60.50 per share. | 03 Sep 2021 | 1,500 | 7,256 | - | 60.5 | 90,744 | Common Stock |